Blockchain Registration Transaction Record

Soligenix Gains EU Orphan Drug Designation for Behçet Disease Treatment

Soligenix receives EU orphan drug designation for dusquetide (SGX945) to treat Behçet Disease, providing market exclusivity and advancing rare disease therapies.

This development matters because Behçet Disease is a rare, chronic autoimmune condition that causes painful inflammation throughout the body, significantly impacting patients' quality of life with limited treatment options. The orphan drug designation accelerates development and approval pathways, potentially bringing effective therapies to patients faster while providing market exclusivity that encourages pharmaceutical investment in rare diseases. For patients, this represents hope for better management of their condition; for investors, it signals progress in Soligenix's pipeline; and for the healthcare system, it addresses an unmet medical need in autoimmune disorders.